AI Article Synopsis

  • Recent studies highlight the benefit of early mechanical circulatory support in cardiogenic shock but lack clear real-time therapeutic targets based on clinical data.
  • A post hoc analysis of the DOREMI trial found that lactate clearance can effectively predict in-hospital survival, with complete lactate clearance showing strong association with patient outcomes.
  • These findings support using lactate clearance as a viable treatment target for improving mortality rates in future cardiogenic shock treatments.

Article Abstract

Background Recent studies have shown improved outcomes in cardiogenic shock through protocols directed toward early identification and initiation of mechanical circulatory support. However, objective therapeutic targets-based on clinical and/or laboratory data-to guide real-time clinical decision making are lacking. Lactate clearance has been suggested as a potential treatment target because of its independent association with mortality. Methods and Results In a post hoc analysis of the DOREMI (Dobutamine Compared to Milrinone in the Treatment of Cardiogenic Shock) trial-a randomized, double-blind, controlled trial comparing milrinone to dobutamine in the treatment of cardiogenic shock-we used prospectively collected lactate data to evaluate lactate clearance as a surrogate marker for in-hospital mortality. In total, 82 (57.7%) patients survived to hospital discharge (survivors). In multivariate logistic regression analysis, complete lactate clearance, percentage lactate clearance, and percentage lactate clearance per hour were independently associated with survival beginning as early as 8 hours after enrollment. Complete lactate clearance was the strongest predictor of survival at all time points, with odds ratios ranging between 2.46 (95% CI, 1.09-5.55; =0.03) at 8 hours to 5.44 (95% CI, 2.14-13.8; <0.01) at 24 hours. Conclusions Complete lactate clearance is a strong and independent predictor of in-hospital survival in patients with cardiogenic shock. Together with previously published data, these results further support the validity of lactate clearance as an appropriate surrogate for mortality and as a potential therapeutic target in future cardiogenic shock trials. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03207165.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075306PMC
http://dx.doi.org/10.1161/JAHA.121.023322DOI Listing

Publication Analysis

Top Keywords

lactate clearance
28
cardiogenic shock
12
lactate
8
clearance surrogate
8
treatment cardiogenic
8
complete lactate
8
clearance percentage
8
percentage lactate
8
clearance
6
surrogate mortality
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!